Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection

Public Health

Volumn 126, Issue 9, 2012, Pages 760-762

  Duarte, R ^a,b,c,d   Carvalho, A ^a,b   Correia, A ^e  

^a Centro de Diagnostico Pneumologico de Vila Nova de Gaia   (Portugal)

^b CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^c University of Porto   (Portugal)

^d Centro de Referência para TBMR na Região Norte   (Portugal)

^e Administração Regional de Saúde do Norte   (Portugal)

Author keywords

Latent tuberculosis infection; Prevention; Treatment; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

DISEASE CONTROL; DISEASE TREATMENT; DRUG PRESCRIBING; INFECTIOUS DISEASE; TUBERCULOSIS;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; PATIENT COMPLIANCE; PORTUGAL; PYRAZINAMIDE; RETROSPECTIVE STUDIES; RIFAMPIN;

EID: 84866023482     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2012.04.008     Document Type: Article

References (8)

1. Dye C., Williams B.G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008, 5:653-662.
2. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982, 60:555-564.
3. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1969, 17:28-106.
4. Mack U., Migliori G.B., Sester M., Rieder H.L., Ehlers S., Goletti D., et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009, 33:956-973.
5. Horsburgh C.R., Goldberg S., Bethel J., Chen S., Colson P.W., Hirsch-Moverman Y., et al. Tuberculosis epidemiologic studies consortium. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137:401-409.
6. Fraser A., Paul M., Attamna A., Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006, 10:19-23.
7. Ministério da Saúde. Direção Geral da Saúde. Dia Mundial da Tuberculose. Situação epidemiológica da tuberculose e resultados em Dezembro de 2008. Programa Nacional de Luta Contra a Tuberculose. Lisboa, 2009. Available at: http://www.dgs.pt.
8. Duarte R., Amado J., Lucas H., Sapage J.M. Treatment of latent tuberculosis infection: update of guidelines, 2006 [in Portuguese]. Rev Port Pneumol 2007, 13:397-418. Portuguese Society of Pulmonology.